At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 53 enrolled
Drug / intervention
Rabipur® +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Randomized, Open Label, Controlled, Dose-Escalation, Phase I Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of One or Two Administrations of Candidate Rabies mRNA Vaccine CV7202 in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating Rabipur® and Rabies mRNA vaccine CV7202 for Rabies. Completed, enrolled 53 participants across 2 sites in 2 countries.
Detailed Summary
The primary objective of this clinical study is to assess the safety, and reactogenicity of CV7202 mRNA-rabies vaccine in healthy adults. Immunogenicity is also assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRabies
CountriesBelgium, Germany
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartOct 2018
First PostedOct 2018
Primary CompletionNov 2021
TodayJul 2026
First PostedOct 19, 2018
Enrollment StartOct 12, 2018
Primary CompletionNov 23, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.7 years ago
Interventions
Rabipur®biological
3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
Rabies mRNA vaccine CV7202biological
CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
Rabies mRNA vaccine CV7202biological
CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
Rabies mRNA vaccine CV7202biological
CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm